Biocon aims to list Biocon Biologics over the next two to three years - (India Infoline via NewsPoints Desk)

  • Biocon’s CEO Siddharth Mittal said the company plans to list its biosimilar unit Biocon Biologics on Indian capital markets in the next two to three years, reported India Infoline.

  • The drugmaker couldn’t comment on a specific timeline as it is depends upon market conditions and the company’s business performance.

  • Biocon aims to generate $1 billion in revenue from the biosimilars segment by fiscal year 2022. 

To read more NewsPoints articles, click here.